HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $25
HC Wainwright & Co. analyst Andrew Fein maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $20 to $25.
SVB Leerink Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $21
SVB Leerink analyst Marc Goodman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $27 to $21.
ACADIA Pharmaceuticals: Q2 Earnings Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
8 Analysts Have This to Say About ACADIA Pharmaceuticals
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:
FDA Asks For Additional Study For Acadia’s Pimavanserin In Alzheimer’s-Associated Delusions
The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ:ACAD) regarding its supplemental marketing application for pimavanserin in…
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap of Monday’s Biotech Catalysts – End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.
Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome.
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Lowers Price Target to $22
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and lowers the price target from $24 to $22.